

## Progen Pharmaceuticals

[View the current Progen Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/8546-Progen+Pharmaceuticals.html)

(<http://www.bioportfolio.com/bi corporate/8546-Progen+Pharmaceuticals.html>)

### Contact Details:

16 Benson St,  
Toowong  
Queensland  
4066  
Australia

Tel: +61-7-3842-3333  
Fax: +61-7-3720-9624  
Email:

Progen Pharmaceuticals Limited (NASDAQ:PGLA; ASX: PGL) is a globally focused biotechnology company committed to improving patient outcomes through discovery and development of small molecule-based cancer therapeutics. The company has an intimate understanding of the role of heparan sulfate, a complex sugar, in cancer disease processes and have developed a small-molecule drug development program in this area. PI-88 is the first product produced from this research and promising signs of efficacy in humans are emerging from the clinical program. A Phase II clinical trial program across multiple cancers is currently underway. Areas of investigation include lung cancer, (NSCLC), primary liver cancer (hepatocellular carcinoma), multiple myeloma and melanoma (for which PI-88 has received Orphan Drug status from the US FDA) and prostate cancer. This is supplemented by an innovative drug discovery program that intends to funnel future compounds through the pipeline and into human trials. PI-166 has been in-licensed for clinical development for the treatment of end-stage primary liver cancer and is currently undergoing Phase Ib clinical development in Australia. New innovative cancer therapies are currently being screened to supplement the company's cancer development pipeline. Progen's manufacturing strength currently lies in the production of our lead product PI-88 for our on going clinical trials.

### Recent Publications by Progen Pharmaceuticals:



- [The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer.](#)

*PURPOSE: PG11047 is a polyamine analog currently in Phase I trials for...* 14th October, 2009  
Progen Pharmaceuticals Ltd, PO Box 2403, Toowong, Brisbane, QLD 4066,- Cancer Chemother  
Pharmacol. 2009 Dec;65(1):191-5. Epub 2009 Aug 15. ([DOI Direct Link](#))

- [Synthesis of a heparan sulfate mimetic disaccharide with a conformationally locked residue from a common intermediate.](#)

*A simple mimetic of a heparan sulfate disaccharide sequence that binds to...* 13th October, 2009  
Drug Design Group, Progen Pharmaceuticals Limited, Brisbane, Qld 4066,- Carbohydr Res. 2009 Nov 23;344(17):2394-8. Epub 2009 Sep 19. ([DOI Direct Link](#))

- [Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening.](#)

*The role that heparanase plays during metastasis and angiogenesis in...* 15th September, 2009  
Drug Design Group, Progen Pharmaceuticals, Toowong, Qld 4066, Australia.- Anal Biochem. 2009 Sep 11. ([DOI Direct Link](#))

- [A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins.](#)

*A surface plasmon resonance-based solution affinity assay is described for...* 21st August, 2009  
Drug Design Group, Progen Pharmaceuticals Ltd, Darra, QLD, Australia.- Glycoconj J. 2009 Jul;26(5):577-87. Epub 2008 Nov 26. ([DOI Direct Link](#))

- [The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy.](#)

*Heparan sulfate mimetics, which we have called the PG500 series, have been...* 10th April, 2009  
Drug Design Group, Progen Pharmaceuticals Ltd, P.O. Box 2403, Toowong,- Invest New Drugs. 2009 Apr 9. ([DOI Direct Link](#))

- [The calculation of polar surface area from first principles: an application of quantum chemical topology to drug design.](#)

*The calculation of polar surface areas (PSA) from the electron density...* 30th July, 2008  
Drug Design Group, Progen Pharmaceuticals Ltd. PO Box 2403, Toowong 4066- ChemMedChem. 2008 Mar;3(3):445-53. ([DOI Direct Link](#))

- [Synthesis and heparanase inhibitory activity of sulfated manooligosaccharides related to the antiangiogenic agent PI-88.](#)

*A stepwise synthetic route to the manooligosaccharides from the neutral...* 21st February, 2008  
Drug Design Group, Progen Pharmaceuticals Limited, PO Box 2403, Toowong,- Bioorg Med Chem. 2008 Jan 15;16(2):699-709. Epub 2007 Oct 18. ([DOI Direct Link](#))

- [Design, synthesis, FGF-1 binding, and molecular modeling studies of conformationally flexible heparin mimetic disaccharides.](#)

*Disaccharide mimetics of a heparin sequence that binds to fibroblast...* 13th February, 2008  
Drug Design Group, Progen Pharmaceuticals Limited, PO Box 2403, Toowong,- Bioorg Med Chem Lett. 2008 Jan 1;18(1):344-9. Epub 2007 Oct 25. ([DOI Direct Link](#))

## Press Releases on Progen Pharmaceuticals:

["As an Industry, We've Been too Focused on Regulatory Approval," Says Solvay Pharmaceuticals Eric Rambeaux at the Pharma Marketing Summit.](#)

26th November, 2009

LONDON, November 26 /PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeforpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes

[Onyx Pharmaceuticals Announces December 2009 Investor Events](#)

25th November, 2009

Onyx Pharmaceuticals, Inc.

EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7,

[Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference](#)

25th November, 2009

Ardea Biosciences, Inc.

SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals' service division and Pyxis Discovery announced today that they have signed a collaborative agreement

[iThemba Pharmaceuticals \(Pty\) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering](#)

25th November, 2009

Reportlinker

NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective <http://www>

[Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective](#)

25th November, 2009

## BioNews Results for Progen Pharmaceuticals



- [Progen: Legal Update EUR' Settlement Reached](#)  
*Pharma Live: Nov 20 2009 8:39PM Matching: progen pharmaceuticals*
- [Morphine may accelerate cancer growth, research suggests](#)  
*Times Colonist: Nov 20 2009 5:04PM Matching: progen pharmaceuticals*
- [Pain Drug May Speed Cancer Growth](#)  
*NewsMax.com: Nov 19 2009 3:21PM Matching: progen pharmaceuticals*
- [Pain drug morphine may accelerate cancer growth](#)  
*CHINAdaily: Nov 19 2009 4:27AM Matching: progen pharmaceuticals*
- [Pain drug morphine may accelerate cancer growth](#)  
*Reuters India: Nov 19 2009 1:36AM Matching: progen pharmaceuticals*
- [Morphine may accelerate cancer growth, research suggests](#)  
*Canada.com: Nov 19 2009 12:25AM Matching: progen pharmaceuticals*
- [Pain drug morphine may accelerate cancer growth](#)  
*Reuters UK: Nov 18 2009 11:00PM Matching: progen pharmaceuticals*
- [Pain Drug Morphine May Accelerate Cancer Growth](#)  
*ABC News: Nov 18 2009 10:18PM Matching: progen pharmaceuticals*
- [Pain drug morphine may accelerate cancer growth](#)  
*Reuters: Nov 18 2009 10:16PM Matching: progen pharmaceuticals*
- [Pain drug morphine may accelerate cancer growth](#)  
*National Post: Nov 18 2009 10:06PM Matching: progen pharmaceuticals*

- [Pain drug morphine may accelerate cancer growth](#)  
*Interactive Investor International: Nov 18 2009 10:06PM Matching: progen pharmaceuticals*
- [Pain drug morphine may accelerate cancer growth](#)  
*Yahoo! News: Nov 18 2009 9:58PM Matching: progen pharmaceuticals*
- [Pain drug morphine may accelerate cancer growth](#)  
*Reuters via Yahoo!: Nov 18 2009 9:50PM Matching: progen pharmaceuticals*
- [Pain drug morphine may accelerate cancer growth](#)  
*Reuters via Yahoo!: Nov 18 2009 9:50PM Matching: progen pharmaceuticals*
- [CORRECTING and REPLACING Progenics Announces Third Quarter 2009 Financial Results](#)  
*Pharmacy Choice: Nov 10 2009 6:08AM Matching: progen pharmaceuticals*

#### Progen Pharmaceuticals Clinical Trials:



- [Phase III Study of PI-88 in Post-Resection Hepatocellular Carcinoma](#)

#### Progen Pharmaceuticals Patents:



- 7491849- [Oligoamine compounds and derivatives thereof for cancer therapy](#)
- 7453011- [Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast

service

- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

